ATS Partner Grants: ATS/Fisher & Paykel Healthcare Research Grant in Nasal High Flow

Overview

ATS/Fisher & Paykel Healthcare Research Grant in Nasal High Flow

* 1 grant available
* $50,000 per year for 2 years

Target Audience

Early-stage investigators interested in research on respiratory support with nasal high flow therapy in hospital patients.

The focus of this research grant is proposals on respiratory support with nasal high flow therapy in stable, adult patients. Patients must be in the hospital care during their involvement in the project. Nasal high flow (NHF) therapy refers to a typical range from 20 to 70 L/min of heated, humidified air with or without supplemental oxygen delivered to the nares via the purposely designed nasal cannula interface.

Nasal high flow (NHF) therapy refers to a typical range from 20 to 70 L/min of heated, humidified gas delivered to the nares via purposely designed nasal cannula. Flow settings and fraction of delivered supplemental oxygen during the therapy vary depending on the patient’s level of compliance and severity of disease. There has been a recent rapid uptake in the use of NHF in acute care settings, primarily to treat hypoxemic respiratory failure, and the therapy has been extensively used around the world during the COVID-19 pandemic. Apart from efficient oxygenation due to the prevention of room air entrainment, NHF provides respiratory support that may be seen in the reduction of the breathing frequency and the work of breathing. Positive airway pressure and the reduction of re-breathing caused by the clearance of expired gas in the upper airways are believed to be the key mechanisms that may improve the ventilation efficiency during NHF. Saturation with water of heated gas maintains hydration of the airway surface liquid and preserves mucociliary function.

NHF therapy is increasingly used in stable patients with lung disease or post-surgery who require support during unassisted breathing with little or no supplemental oxygen. Fisher & Paykel Healthcare, in collaboration with the American Thoracic Society, seeks to offer a research award to investigators interested in studying these potential benefits of NHF in hospital patients. The prospective study could be aimed at better understanding the mechanisms of action of this therapy, or on achieving improvements in a variety of likely outcomes.

Applicants may request up to $50,000 per year for 2 years. NHF equipment and consumables can be provided for the study by Fisher & Paykel Healthcare at no cost. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution..

Eligibility

_You can learn more about this opportunity by visiting the funder's website._

* Applicants or at least one of the key personnel must be an ATS member at the time of application
* The principal investigator must be a full ATS member at the time the grant is awarded
* Applicants must have completed their primary research training (PhD or sub-specialty fellowship) by September 1, 2024
* Applicants must have a firm commitment from their home institution for a faculty position by the time the award is disbursed (May 2025)
* Applicants must not have received 2 ATS Research Program grants or be a current ATS Research Program Awardee 
* Applicants who are not US citizens but are currently based in the US must hold a Visa that spans the project period of the grant
* We do accept submissions by international and domestic applicants unless otherwise specified.

_You must be a member of this organization to apply for this award - become a member. Applicants or at least one of the key personnel must be an ATS member at the time of application. The principal investigator must be a full ATS member at the time the grant is awarded._